A detailed history of Ameriprise Financial Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 28,230 shares of ETNB stock, worth $245,036. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,230
Previous 13,589 107.74%
Holding current value
$245,036
Previous $100,000 116.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$7.03 - $10.05 $102,926 - $147,142
14,641 Added 107.74%
28,230 $216,000
Q3 2024

Nov 14, 2024

BUY
$7.36 - $9.66 $100,015 - $131,269
13,589 New
13,589 $100,000
Q3 2023

Nov 14, 2023

SELL
$15.06 - $19.41 $544,343 - $701,574
-36,145 Reduced 9.44%
346,946 $5.36 Million
Q2 2023

Aug 14, 2023

BUY
$14.15 - $22.03 $1.86 Million - $2.89 Million
131,107 Added 52.03%
383,091 $7.26 Million
Q1 2023

May 15, 2023

BUY
$10.48 - $16.94 $2.64 Million - $4.27 Million
251,984 New
251,984 $3.84 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $403M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.